Human Papillomaviruses pp 445-462

Part of the Methods in Molecular Medicine book series (MIMM, volume 119)

Generation of HPV Pseudovirions Using Transfection and Their Use in Neutralization Assays

  • Christopher B. Buck
  • Diana V. Pastrana
  • Douglas R. Lowy
  • John T. Schiller

Summary

It has recently become possible to generate high-titer papillomavirus-based gene-transfer vectors. The vectors, also known as papillomavirus pseudoviruses (PsV), have been useful for studying papillomavirus assembly, entry, and neutralization, and may have future utility as laboratory gene-transfer tools or vaccine vehicles. This chapter outlines a simple method for production of PsV and their use in a high-throughput papillomavirus neutralization assay. The production method is based on transfection of a 293 cell line, 293TT, engineered to express high levels of SV40 large T antigen. The cells are co-transfected with codon-modified papillomavirus capsid genes, L1 and L2, together with a pseudogenome plasmid containing the SV40 origin of replication. Pseudogenome encapsidation within L1/L2 capsids is largely sequence independent, and plasmids entirely lacking PV sequences can be packaged efficiently, provided they are less than 8 kilobases in size. Non-infectious virus-like particles (VLPs) can also be produced after transfection of 293TT cells with L1 alone. Efficient purification of the PsV or VLPs is achieved by Optiprep (iodixanol) density gradient ultracentrifugation. Using these methods, it is possible to produce highly purified PsV with yields of at least 109 transducing units from a single 75-cm2 flask of cells. PsV encapsidating a secreted alkaline phosphatase (SEAP) reporter plasmid were used to develop a high-throughput in vitro neutralization assay in a 96-well plate format. Infection of 293TT cells is monitored by SEAP activity in the culture supernatant, using a highly sensitive chemiluminescent reporter system. Antibody-mediated PsV neutralization is detected by a reduction in SEAP activity. The neutralization assay has similar analytic sensitivity to, and higher specificity than, a standard VLP-based enzyme-linked immunosorbent assay (ELISA).

References

  1. 1.
    Meyers, C. and Laimins, L. A. (1994) In vitro systems for the study and propagation of human papillomaviruses. Curr. Top. Microbiol. Immunol. 186, 199–215.PubMedGoogle Scholar
  2. 2.
    Roden, R. B., Greenstone, H. L., Kirnbauer, R., et al. (1996) In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70, 5875-5883.Google Scholar
  3. 3.
    Unckell, F., Streeck, R. E., and Sapp, M. (1997) Generation and neutralization of pseudovirions of human papillomavirus type 33. J. Virol. 71, 2934–2939.PubMedGoogle Scholar
  4. 4.
    Touze, A. and Coursaget, P. (1998) In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 26, 1317–1323.PubMedCrossRefGoogle Scholar
  5. 5.
    Schwartz, S. (2000) Regulation of human papillomavirus late gene expression. Ups J Med Sci 105, 171–192.PubMedGoogle Scholar
  6. 6.
    Fu, X. Y. and Manley, J. L. (1987) Factors influencing alternative splice site utilization in vivo. Mol. Cell Biol. 7, 738–748.PubMedGoogle Scholar
  7. 7.
    Andersen, K. J., Vik, H., Eikesdal, H. P., and Christensen, E. I. (1995) Effects of contrast media on renal epithelial cells in culture. Acta Radiol. Suppl. 399, 213–218.PubMedGoogle Scholar
  8. 8.
    Buck, C. B., Pastrana, D. V., Lowy, D. R., and Schiller, J. T. (2004) Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78, 751–757.PubMedCrossRefGoogle Scholar
  9. 9.
    Leder, C., Kleinschmidt, J. A., Wiethe, C., and Muller, M. (2001) Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol. 75, 9201–9209.PubMedCrossRefGoogle Scholar
  10. 10.
    Pastrana, D. V., Buck, C. B., Pang, Y. Y., et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205–216.PubMedCrossRefGoogle Scholar
  11. 11.
    Buck, C. B., Thompson, C. D., Pang, Y.-Y. S., Lowy, D. R., and Schiller, J. T. (2005) Maturation of papillomavirus capsids. J. Virol. 79, 2839–2846.PubMedCrossRefGoogle Scholar
  12. 12.
    Selinka, H. C., Giroglou, T., Nowak, T., Christensen, N. D., and Sapp, M. (2003) Further evidence that papillomavirus capsids exist in two distinct conformations. J. Virol. 77, 12,961–12,967.PubMedCrossRefGoogle Scholar
  13. 13.
    Roden, R. B., Lowy, D. R., and Schiller, J. T. (1997) Papillomavirus is resistant to desiccation. J. Infect. Dis. 176, 1076–1079.PubMedCrossRefGoogle Scholar
  14. 14.
    Volkin, D. B., Shi, L., and Sanyal, G. (2002) Stabilized human papillomavirus formulations. U.S. patent 6,358,744 B1.Google Scholar
  15. 15.
    Joyce, J. G., Tung, J. S., Przysiecki, C. T., et al. (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274, 5810–5822.PubMedCrossRefGoogle Scholar
  16. 16.
    Klasse, P. J. and Sattentau, Q. J. (2002) Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83, 2091–2108.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Christopher B. Buck
    • 1
  • Diana V. Pastrana
    • 1
  • Douglas R. Lowy
    • 1
  • John T. Schiller
    • 1
  1. 1.Laboratory of Cellular Oncology, Center for Cancer ResearchNational Cancer InstituteBethesda

Personalised recommendations